Stryker Corp Stock Price, News & Analysis

Stryker (NYSE:SYK) has announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, , which will create a new company called VB Spine, . The transaction includes a binding offer to acquire Stryker's spinal implants business in France and plans to sell related international operations.

After closing, VB Spine will become a strategic partner to Stryker with exclusive access to Mako Spine and Copilot for use with VB Spine's implants. The deal aims to enhance focus for both companies and is expected to achieve faster growth and deliver greater value for stakeholders.

The transaction is expected to close in the U.S. in the first half of 2025, subject to customary closing conditions. Barings, will serve as an investor and financial partner to Viscogliosi Brothers in this transaction.

Stryker (NYSE: SYK) announced significant leadership changes as Glenn S. Boehnlein will retire from his position as Vice President, Chief Financial Officer after 22 years with the company. Preston Wells, currently serving as Group CFO for Stryker's Orthopaedics Group, will take over as Vice President, Chief Financial Officer effective April 1, 2025.

Wells brings extensive experience from various finance roles at Stryker, including leadership in Investor Relations, Enterprise Financial Planning & Analysis, and sales finance operations. His current role involves collaboration with Joint Replacement, Trauma & Extremities, Spine, and Digital, Robotics, and Enabling Technologies teams. Before joining Stryker, Wells accumulated 17 years of senior accounting and financial management experience at Dialight and Johnson & Johnson. He holds a bachelor's in accounting from Bucknell University and an MBA in Supply Chain Management from Lehigh University.

Stryker (NYSE:SYK) reported strong Q4 and full-year 2024 results, with Q4 reported net sales increasing 10.7% to $6.4 billion and full-year sales rising 10.2% to $22.6 billion. The company achieved organic net sales growth of 10.2% for both periods.

Q4 adjusted EPS increased 15.9% to $4.01, while full-year adjusted EPS grew 15.0% to $12.19. However, reported EPS decreased 52.7% to $1.41 in Q4 and 5.9% to $7.76 for the full year, primarily due to $818 million in non-cash charges for goodwill and other impairments related to the Spine business.

For 2025, Stryker expects organic net sales growth between 8.0% and 9.0%, with adjusted EPS projected at $13.45-$13.70. The company anticipates closing the Inari acquisition in February 2025, expected to contribute approximately $590 million in sales for the stub period.

Stryker (NYSE: SYK) has initiated a cash tender offer through its subsidiary, Eagle 1 Merger Sub, to acquire all outstanding shares of Inari Medical (NASDAQ: NARI) for $80.00 per share in cash. This offer follows the merger agreement announced on January 6, 2025.

The tender offer is set to expire on February 18, 2025, at one minute past 11:59 p.m. Eastern Time, unless extended. The completion of the deal is subject to several conditions, including the tender of at least a majority of Inari's outstanding shares and regulatory approvals. The transaction is expected to close by the end of Q1 2025.

Both companies have filed required documentation with the SEC, including Stryker's tender offer statement (Schedule TO) and Inari's recommendation to stockholders (Schedule 14D-9) to accept the offer.

Stryker (NYSE: SYK) has announced a definitive agreement to acquire Inari Medical (NASDAQ: NARI) for $80 per share in cash, representing a total equity value of approximately $4.9 billion. The acquisition will strengthen Stryker's position in the peripheral vascular segment, specifically in venous thromboembolism (VTE) treatment.

Inari's product portfolio, which includes mechanical thrombectomy solutions for peripheral vascular diseases like deep vein thrombosis and pulmonary embolism, complements Stryker's Neurovascular business. VTE affects up to 900,000 lives annually in the United States alone.

The transaction, unanimously approved by both companies' boards, is expected to close by the end of Q1 2025. The deal is subject to conditions including a minimum tender of majority shares and Hart-Scott-Rodino Antitrust clearance. Financial impact details will be discussed during Stryker's Q4 2024 earnings call on January 28, 2025.

Stryker (NYSE:SYK) has scheduled the release of its fourth quarter and full year 2024 financial results for Tuesday, January 28, 2025. The company will issue a press release containing summary financial information at approximately 4:05 p.m. ET, followed by a webcast at 4:30 p.m. ET to discuss the results.

The financial report will cover the period ending December 31, 2024. Investors and interested parties can access the webcast through Stryker's website under Events & Presentations. An archive of the webcast will be made available on the company's website two hours after the live call concludes.

Stryker (NYSE:SYK) has announced a quarterly dividend increase of 5.0%, declaring a payment of $0.84 per share. The dividend will be payable on January 31, 2025, to shareholders of record as of December 31, 2024. The company's Chair and CEO Kevin Lobo attributed this increase to Stryker's strong financial performance, aligning with their capital allocation priorities.

Stryker (NYSE: SYK) has introduced the Oculan Lighting Platform, an advanced surgical lighting solution designed to enhance operating room visualization. The platform features proprietary Fly Eye technology for even light distribution, consistent illumination, and specialized modes like Auto lux and Microspot for uniform brightness in deep cavities. The system includes SHD Mode for improved contrast and tissue differentiation, along with heat minimization features for surgeon comfort during lengthy procedures. The platform is compatible with existing Stryker surgical lights and offers multiple control points for streamlined workflow.

Stryker (NYSE:SYK) has launched the next generation of SurgiCount+, now integrated with Triton technology, to address retained surgical sponges and blood loss assessment challenges. The system features AI technology that differentiates blood from other fluids and includes a Bluetooth scale for weighing blood-soaked items. The solution helps prevent retained surgical items, which occur in 88% of cases with false correct counts, and assists in managing maternal hemorrhage cases, of which 70% are preventable. The integrated platform streamlines workflow efficiency, reduces manual data entry errors, and provides real-time EMR integration.